May 13th 2024
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Anetumab Ravtansine Does Not Improve PFS Vs Vinorelbinein Patients With MPM
April 13th 2022Anetumab ravtansine did not show superior progression-free survival or overall survival in the second-line treatment setting for patients with mesothelin-expressing malignant pleural mesothelioma, according to results from the 15743 study.
Read More
Nivolumab Plus Chemotherapy Represents New SOC for Resectable NSCLC
April 11th 2022Findings of CheckMate 816 show improved event-free survival and partial complete response and promising overall survival results with the use of neoadjuvant nivolumab in combination with chemotherapy for patients with resectable NSCLC.
Read More
Multiple Immune Pathway Inhibition Bests ICI Therapy in Resectable, Early-Stage NSCLC
April 11th 2022Targeting multiple immune cell pathways may elicit better major pathologic and pathologic complete responses in patient with resectable, early-stage non–small cell lung cancer versus immune checkpoint inhibition alone.
Read More
FDA Denies Approval of Sintilimab With Chemotherapy for Nonsquamous NSCLC
March 24th 2022The FDA has issued a complete response letter denying approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as frontline treatment for patients with nonsquamous non–small cell lung cancer.
Read More
Adjuvant Pembrolizumab Improves DFS in Stage IB-IIIA Non-Small Cell Lung Cancer
March 21st 2022Findings show adjuvant pembrolizumab to significantly improve disease-free survival in patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression
Read More
Dosing Begins in Phase 1/2 Study of Reqorsa Plus Osimertinib in Advanced NSCLC
March 7th 2022Dosing has begun in patients with advanced non–small cell lung cancer in the phase 1/2 Acclaim-1 clinical trial of quaratusugene ozeplasmid in combination with osimertinib after disease progression on osimertinib alone.
Read More
Early Engagement With FDA Key for Oncologic Drug Developers
February 28th 2022Jorge Nieva, MD, explains how international drug developers should approach the approval application process after a biologics license application for sintilimab plus chemotherapy for the treatment of nonsquamous non–small cell lung cancer was not successful.
Watch
FDA Grants Priority Review to Neoadjuvant Nivolumab Plus Chemotherapy for Resectable NSCLC
February 28th 2022The FDA will conduct a speedy review of the supplemental biologics license application filed for nivolumab in combination with chemotherapy and granted it priority review for the neoadjuvant treatment of patients with resectable non–small cell lung cancer.
Read More
Sintilimab as a Cost-Effective Alternative for Nonsquamous NSCLC
February 22nd 2022Jorge Nieva, MD, discusses why he voted differently from the other members of the FDA’s Oncologic Drug Advisory Committee regarding sintilimab in combination with chemotherapy for the first-line treatment of patients with nonsquamous non–small cell lung cancer.
Watch